## **CLAIMS**

A method of screening for agents which can regulate the activity of a human 1. phospholipase-like enzyme, comprising the steps of:

contacting a test compound with a polypeptide comprising an amino acid sequence which is at least about 78% identical to the amino acid sequence shown in SEQ ID NO:2; and

detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential therapeutic agent for regulating the activity of the human phospholipase-like enzyme.

10

15

20

25

5

- 2. The method of claim 1 wherein the step of contacting is in a cell.
- The method of claim 2 wherein the cell is in vitro. 3.
- The method of claim 1 wherein the step of contacting is in a cell-free 4. system.
  - The method of claim 1 wherein the polypeptide comprises a detectable label. 5.

label.

- The method of claim 1 wherein the test compound comprises a detectable 6.
- 7. The method of claim 1 wherein the test compound displaces a labeled ligand which is bound to the polypeptide.
  - 8. The method of claim 1 wherein the polypeptide is bound to a solid support.
- The method of claim 1 wherein the test compound is bound to a solid 9. support.
- 10. A method of screening for agents which regulate an activity of a human phospholipase-like enzyme, comprising the steps of:

contacting a test compound with a polypeptide comprising an amino acid sequence which is at least about 78% identical to the amino acid sequence shown in SEQ ID NO:2; and

detecting a phospholipase activity of the polypeptide, wherein a test compound which increases the phospholipase activity is identified as a potential therapeutic agent for increasing the activity of the human phospholipase-like enzyme, and wherein a

test compound which decreases the phospholipase activity of the polypeptide is identified as a potential therapeutic agent for decreasing the activity of the human phospholipase-like enzyme.

- The method of claim 10 wherein the step of contacting is in a cell. 11.
- The method of claim 11 wherein the cell is in vitro. 12.
- The method of claim 10 wherein the step of contacting is in a cell-free 13. system.
- A method of screening for agents which regulate an activity of a human 14. phospholipase-like enzyme, comprising the steps of:

contacting a test compound with a product encoded by a polynucleotide which comprises a nucleotide sequence which is at least about 50% identical to the complement of the nucleotide sequence shown in SEQ ID NO:1; and

detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential therapeutic agent for regulating the activity of the human phospholipase-like enzyme.

- The method of claim 14 wherein the product is a polypeptide. 15.
- 16. The method of claim 14 wherein the product is RNA.
- 17. A method of reducing activity of a human phospholipase-like enzyme, comprising the step of:

contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising a nucleotide sequence which is at least about 50% identical to the nucleotide sequence shown in SEQ ID NO:1, whereby the activity of the human phospholipase-like enzyme is reduced.

- The method of claim 17 wherein the product is a polypeptide. 18.
- The method of claim 18 wherein the reagent is an antibody. 19.
- 20. The method of claim 17 wherein the product is RNA.
- 21. The method of claim 20 wherein the reagent is an antisense oligonucleotide.
- 22. The method of claim 20 wherein the reagent is a ribozyme.
- 23. The method of claim 17 wherein the cell is in vitro.

5

10

15

20

25

5

10

15

- 24. The method of claim 17 wherein the cell is in vivo.
- 25. A pharmaceutical composition, comprising:

a reagent which specifically binds to a product encoded by a polynucleotide comprising a nucleotide sequence which is at least about 50% identical to the nucleotide sequence shown in SEQ ID NO:1; and

a pharmaceutically acceptable carrier.

- 26. The pharmaceutical composition of claim 25, wherein the reagent is an antibody.
- 27. The pharmaceutical composition of claim 25, wherein the reagent is an antisense oligonucleotide.
- 28. The pharmaceutical composition of claim 25, wherein the reagent is a ribozyme.
- 29. A pharmaceutical composition, comprising:

  an expression construct encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2; and

  a pharmaceutically acceptable carrier.